Dilated Cardiomyopathy Therapeutic Pipeline Market Review H2 2014 Report at ReportsnReports.com

Share Article

ReportsnReports.com adds “Dilated Cardiomyopathy Pipeline Review, H2 2014” to its store. The report provides an overview of the Dilated Cardiomyopathy therapeutic pipeline.

The report "Dilated Cardiomyopathy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Dilated Cardiomyopathy. Dilated cardiomyopathy is a condition in which the heart becomes damaged and inflamed and cannot pump blood powerfully. The decreased heart function can affect the lungs, liver and other body systems. Dilated cardiomyopathy might not cause symptoms, but for some people it can be serious. The condition affects people of all ages including infants and children but is most common in men ages 20 to 60. Symptoms of Dilated cardiomyopathy can occur at any age and may include heart failure, swelling of the lower extremities, fatigue, weight gain, fainting, palpitations, lightheadedness and chest pain.

It also reviews key players involved in the therapeutic development for Dilated Cardiomyopathy and special features on late-stage and discontinued projects. Companies discussed in this Dilated Cardiomyopathy Pipeline Review H2 2014 report include Array BioPharma Inc., Kasiak Research Pvt. Ltd., Sanofi, Vericel Corporation, Zensun (Shanghai) Sci & Tech Co., Ltd.

Drugs profile discussed in this Dilated Cardiomyopathy Pipeline Review H2 2014 report include ARRY-797, CAP-1002, ixmyelocel-T, Neucardin, Refacell-DCM, Small Molecule for Dilated Cardiomyopathy. Complete Report is Available @ http://www.reportsnreports.com/reports/321901-dilated-cardiomyopathy-pipeline-review-h2-2014.html .

Featured News & Press Releases

  •     Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
  •     Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
  •     Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T
  •     Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting
  •     May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients
  •     May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions
  •     Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T
  •     Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT

DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy
May 17, 2011: Aastrom To Present Results From Two Studies of Ixmyelocel-T At International Society For Cellular Therapy Meeting

Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=321901 .

List of Tables
Number of Products under Development for Dilated Cardiomyopathy, H2 2014 7
Number of Products under Development for Dilated Cardiomyopathy - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H2 2014 13
Dilated Cardiomyopathy - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 14
Dilated Cardiomyopathy - Pipeline by Sanofi, H2 2014 15
Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H2 2014 16
Dilated Cardiomyopathy - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Dilated Cardiomyopathy Therapeutics - Recent Pipeline Updates, H2 2014 38
Dilated Cardiomyopathy - Dormant Projects, H2 2014 46

List of Figures
Number of Products under Development for Dilated Cardiomyopathy, H2 2014 7
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Top 10 Targets, H2 2014 19
Number of Products by Stage and Top 10 Targets, H2 2014 20
Number of Products by Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Top 10 Routes of Administration, H2 2014 23
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 24
Number of Products by Top 10 Molecule Types, H2 2014 25
Number of Products by Stage and Top 10 Molecule Types, H2 2014 26

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
ReportsnReports
+1 (888) 391-5441
Email >
@LifeSciReports
Follow >
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website